University of California, Irvine researchers have discovered a method to design and use selective inhibitors against a family of nitric oxide synthetase isoforms that control the production of nitric oxide (NO). X-ray crystallography was utilized to generate isoform specific NOS-inhibitor complexes with unique structural characteristics. An overproduction of NO has been linked to several diseases, conditions and addictions, including: ischemic injury and other brain damage after stroke, migraine headache, Alzheimer's Disease, colitis, tissue damage, inflammation, septic shock and rheumatoid arthritis.
This discovery provides for drug discovery and design protocols for isoform drugs that target NOS isoforms and reduce NO production.
|United States Of America||Issued Patent||7,056,945||06/06/2006||2002-460|